Bio-Techne Surges to 480th Most Traded Stock with 2 Billion Turnover

On June 25, 2025, Bio-Techne (TECH) experienced a significant surge in trading volume, with a turnover of 2.00 billion, marking a 152.74% increase from the previous day. This substantial rise in trading volume positioned Bio-Techne as the 480th most traded stock for the day. The company's stock price also saw a notable increase, rising by 3.78% over the past two days, with a cumulative gain of 5.25%.

Bio-Techne's recent performance can be attributed to several factors within the biotechnology sector. Notably, Gilead Sciences secured a $750 million deal with Kymera Therapeutics, which could potentially influence market sentiment and investor confidence in the biotech industry. This deal highlights the growing interest and investment in innovative biotech solutions, which may have positively impacted Bio-Techne's stock price.

Additionally, the biotech sector has seen other significant developments, such as the FDA's approval of Datroway for EGFR-mutated lung cancer, a joint effort by AstraZeneca and Daiichi Sankyo. This approval underscores the regulatory progress and market acceptance of new biotech treatments, which could further bolster investor optimism in the sector.

Furthermore, the biotech industry continues to witness advancements in drug development and genetic engineering, as evidenced by the latest research and innovations reported in various biotech news outlets. These developments contribute to a positive outlook for the sector, potentially driving investor interest and stock performance for companies like Bio-Techne.